首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >CONDITIONAL SITE-SPECIFIC RECOMBINATION IN MAMMALIAN CELLS USING A LIGAND-DEPENDENT CHIMERIC CRE RECOMBINASE
【24h】

CONDITIONAL SITE-SPECIFIC RECOMBINATION IN MAMMALIAN CELLS USING A LIGAND-DEPENDENT CHIMERIC CRE RECOMBINASE

机译:配体依赖性嵌合CRE重组酶在哺乳动物细胞中进行有条件的位点特异性重组

获取原文
获取原文并翻译 | 示例
           

摘要

We have developed a strategy to generate mutant genes in mammalian cells in a conditional manner by employing a fusion protein, Cre-ER, consisting of the loxP site-specific Cre recombinase linked to the ligand-binding domain of the human estrogen receptor. We have established homozygous retinoid X receptor alpha-negative (RXR alpha(-/-)) F9 embryonal carcinoma cells constitutively expressing Cre-ER and have shown that estradiol or the estrogen agonist/antagonist 4 hydroxytamoxifen efficiently induced the recombinase activity, whereas no activity was detected in the absence of ligand or in the presence of the antiestrogen ICI 164,384. Furthermore, using a targeting vector containing a selection marker flanked by loxP sites, we have inactivated one retinoic acid receptor alpha allele in such a line, demonstrating that the presence of the recombinase does not inhibit homologous recombination. Combining this conditional site-specific recombination system with tissue-specific expression of Cre-ER may allow modification of the mammalian genome in vivo in a spatiotemporally regulated manner. [References: 28]
机译:我们已开发出一种策略,可通过使用融合蛋白Cre-ER来有条件地在哺乳动物细胞中产生突变基因,该融合蛋白由与人雌激素受体的配体结合域连接的loxP位点特异性Cre重组酶组成。我们已经建立了组成型表达Cre-ER的纯合类视黄醇X受体α阴性(RXR alpha(-/-))F9胚胎癌细胞,并显示雌二醇或雌激素激动剂/拮抗剂4羟基他莫昔芬有效诱导重组酶活性,而没有活性在不存在配体或抗雌激素ICI 164,384的情况下检测到“Aβ”。此外,使用包含侧翼为loxP位点的选择标记的靶向载体,我们已经灭活了一个这样的视黄酸受体α等位基因,证明重组酶的存在不会抑制同源重组。将这种条件性位点特异性重组系统与Cre-ER的组织特异性表达相结合,可以在体内以时空调控的方式修饰哺乳动物基因组。 [参考:28]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号